Introduction
Although pharmacotherapy represents the first-line treatment for moderate to severe depression, response to antidepressants is marked by inter-individual variability: more than half of all patients will fail to respond adequately to the first antidepressant they are prescribed. 1 Identifying the most effective treatment for a given patient is a long and costly process that not only delays recovery, but also has a negative effect on long-term outcome. Predictors of response would therefore be of important significant clinical value.
Family studies suggest that response to antidepressants is influenced by both genetic and environmental factors. 2, 3 Although pharmacogenetic research has uncovered a number of important candidate genes, environmental factors contributing to antidepressant response remain relatively understudied. Although a number of studies have suggested that the occurrence of a stressful life event (SLE), such as the loss of a loved one, before treatment predicts a more favourable response to antidepressants, 4, 5 others suggest that SLEs are detrimental to treatment, 6, 7 or have no effect. 8 The underlying cause of these discrepant findings is unclear; however, it is possible that the effects of SLEs differ by drug, or are moderated by genotype. 9 An important genetic factor in antidepressant response is variation in the gene (SLC6A4) encoding the serotonin transporter (5-HTT, the primary target of selective serotonin reuptake inhibitors, SSRIs). Two functional polymorphisms in this gene, STin2 and the 5-HTTLPR (serotonin transporterlinked polymorphic region), have been associated with response to SSRIs. [10] [11] [12] [13] [14] Of particular interest is the 5-HTTLPR, a variable number tandem repeat with two common allelic variants, known as 'short' or S and 'long' or L, respectively. A comprehensive meta-analysis, including over 1400 participants revealed a modest association of the short variant of the 5-HTTLPR with poor response and remission to antidepressants. 15 These findings were subsequently replicated by two large pharmacogenetic studies: Genome-based Therapeutic Drugs for Depression (GEN-DEP) 16 and STAR*D, the latter after considering the ethnicity of the study population. 17 Results from the GENDEP study also suggested that the association is drug specific. That is, an effect was observed in patients treated with the primarily pro-serotonergic SSRI escitalopram, but not in those treated with the primarily pro-noradrenergic tricyclic antidepressant nortriptyline.
In addition to its effects on antidepressant response, the 5-HTTLPR has also been shown to moderate the effects of stress on behavioural phenotypes. Individuals with one or more copies of the short allele are more likely to develop depression following a SLE [18] [19] [20] or traumatic stress disorder following a natural disaster. 21 A recent study has suggested that the same interaction may also be relevant in predicting response to antidepressants. 9 Specifically, the occurrence of SLEs at the onset of depression were shown to predict a poorer response to the SSRI fluvoxamine, but only in individuals carrying one or two copies of the S allele.
The GENDEP study (http://gendep.iop.kcl.ac.uk/results. php) was designed to investigate both genetic and clinical predictors of response to two antidepressants with different modes of action: escitalopram (an SSRI) and nortriptyline (a tricyclic antidepressant). 22 Escitalopram is the most selective SSRI in terms of its affinity for the serotonin transporter, whereas nortriptyline has a far greater affinity for the norepinephrine transporter than the serotonin transporter.
Using data collected as part of GENDEP, the aim of the current study was to investigate the effects of antecedent SLEs on response to escitalopram and nortriptyline and determine whether these effects were moderated by 5-HTTLPR genotype. In addition, we explored the moderating effects of 13 further polymorphisms within the serotonin transporter gene (SLC6A4). These included rs25531, a single-nucleotide polymorphism (SNP) suggested to modulate the effects of the 5-HTTLPR on expression of SLC6A4. 23 We hypothesized that as SLC6A4 moderates the effects of stress and encodes the main target for escitalopram, the occurrence of SLEs and any interactions identified would predict response to this drug and not to nortriptyline.
Materials and methods

Design and sample
The data used in this study were collected as part of GENDEP, a multicentre part-randomized pharmacogenomics study. A detailed description of the sample is available elsewhere. 22 In brief, 811 participants aged between 18 and 75 were recruited from nine treatment centres in eight European countries. Participants were of white European parentage and diagnosed with moderate to severe major depressive disorder using the Schedules for Clinical Assessment in Neuropsychiatry. 24 The exclusion criteria were family history of schizophrenia or bipolar affective disorder in a first-degree relative, a personal history of hypomanic or manic episode, schizophrenia, mood incongruent psychotic symptoms, primary substance misuse, primary organic disease and pregnancy. Participants without contraindications were randomly assigned to receive either escitalopram or nortriptyline and those with contraindications for one of the drugs (such as a previous history of an adverse reaction) were non-randomly assigned to receive the alternative medication.
Participants received flexible doses of their allocated drug daily for 12 weeks. Escitalopram was initiated at 10 mg daily and increased to a target dose of 15 mg daily and could be further increased to 20 mg daily (and up to 30 mg if there was clinical agreement that a higher dose was required). Nortriptyline was initiated at 50 mg daily and titrated to a target dose of 100 mg within the first 2 weeks and could be further increased to 150 mg (and up to 200 mg if there was clinical agreement that a higher dose was needed). Other psychotropic medication was prohibited with the exception of occasional use of hypnotics.
Measures
Antidepressant response is a complex phenotype measured as a change in a number of symptoms over time. To capture the full complexity of the phenotype, we evaluated response as a longitudinal outcome. In the GENDEP study, participants' response to antidepressants was assessed weekly throughout the 12 week trial using following three measures of depression severity: the Montgomery-Asberg Depression Rating Scale (MADRS), 25 the Hamilton Depression Rating Scale, 26 and the Beck Depression Inventory. 27 Previous psychometric analyses of the MADRS using the GENDEP data showed this rating scale had the greatest internal consistency of the three measures. 28 As the MADRS was also designed specifically to be sensitive to change over time, 25 in this report, participants' weekly MADRS score was used as the primary measure of their response to both antidepressants.
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The List of Threatening Experiences Questionnaire (LTE-Q) 29 was used to measure the occurrence of SLEs. The LTE-Q is a 12-item, self-report checklist, which was previously adapted to include childbirth and the subjective severity rating of each item. 30 Although the list of threatening experiences includes just 12 items, previous analyses have shown that the measure successfully captures 82.5% of the life events covered in the longer more extensive, and widely accepted, Life Events and Difficulties Schedule. 29 Participants completed the LTE-Q for events that they had experienced in the 6 months before commencing treatment. In all, 674 participants completed the checklist at baseline.
Genetic analyses DNA samples were available for all the 674 participants who completed the LTE-Q. The 5-HTTLPR and putative modifying SNP within the 5-HTTLPR (rs25531) were genotyped and 10 further SNPs were selected to provide 92% coverage of common sequence variants in SLC6A4. Two simple microsatellite repeats, STin2 (SLC6A4, intron 2) and STin4 (SLC6A4, an intron 4 short tandem repeat polymorphism), were also genotyped. In STin2, although 12, 10 and 9 repeats were identified, the occurrence of the 9 repeat was rare with a frequency of o5%, and alleles were therefore dichotomized as either 'long' (12 repeats, 58.8%) or short (10 or 9 repeats, 41.2%). In STin4, 5, 7, 8 and 9 repeats were identified. However, the 7 and 9 repeats were very rare, each with a frequency of o2%. Alleles at STin4 were therefore dichotomized as either 'short' (containing 5-7 repeats, 42.8%) or 'long' (8-9 repeats, 57.2%). Genomic position, minor allele frequency, alleles and Hardy-Weinberg equilibrium P-values for each of the SLC6A4 markers analyzed are given in Table 1 . Linkage disequilibrium between the markers is shown in Supplementary Figure S1 . Further details regarding the selection of polymorphisms, quality control steps and genotyping methods are described elsewhere. 16 
Statistical analyses
Linear mixed models were used to investigate the main effects of SLEs and SLE by genotype interactions on response to both antidepressants over the 12-week trial.
By modelling the relatedness of repeated measurement within the same individual as random effects, mixed models allow response to be assessed longitudinally and, unlike traditional end-point analyses, do not depend on retention of the whole population to measure outcome, or imputation methods that can introduce biases. 31 In previous analyses of the GENDEP data, we reported that treatment centre had a moderate effect on antidepressant response; 28 therefore recruitment centre was modelled as a higher-order random effect in all analyses. All models also included the covariates of gender, age, baseline depression severity (MADRS), randomization status and the linear and quadratic effects of time.
To test the effects of SLEs in predicting antidepressant response, the SLE measure (coded as presence or absence of one or more SLE) was added to the above-mentioned model and change in model fit evaluated using a likelihood ratio test. To detect drug-specific differences, the same analysis was repeated in both drug groups. To test the effects of geneenvironment interactions on antidepressant response, the fit of simpler linear mixed models, containing the main effects of SLE and genotype, were compared (using likelihood ratio tests) to the fit of models also containing the interaction of these factors. Analyses were repeated in each drug group to assess drug-specific differences. There is evidence to suggest that 5-HTTLPR genotypes operate in either a recessive or additive genetic model in both the moderation of the effects of stress and response to antidepressants. 15, 20 Therefore, interactions based on both genotypic models were tested.
The presence of potentially confounding gene-environment correlations was identified using w 2 -tests in both the full sample and samples stratified by treatment arm. All statistical analyses were conducted in STATA version 10.0. 32 
Results
Of the 811 participants recruited in GENDEP, 674 (248 male and 426 female) had both complete genotype and SLE data (mean age 42.3, s.d. 11.48); 383 were treated with escitalopram and 291 with nortriptyline (Supplementary Figure S2) . There was no significant difference in the age, sex, age of onset or baseline depression severity of those included versus those not included in the study owing to missing SLE or genotype data. The mean number of life events reported for the 6 months before treatment was 1.57 (s.d. 1.64). Consistent with previous studies reporting on life events occurring in a relatively short period, the number of life events endorsed was negatively skewed and dichotomizing the SLE variable most appropriately described the data. 19 Using this distinction, Figure 1 ). This effect remained significant on inclusion of only those randomly allocated to receive escitalopram.
Moderating effects of 5-HTTLPR
In the overall sample and in the nortriptyline-treated patients, the addition of the gene-environment interaction to a simpler model containing only the main effects of these factors impaired model fit (all likelihood ratio tests P40.1). This was the same when assuming either a recessive or additive model genetic model. In the escitalopram-treated group, the inclusion of an interaction, assuming a recessive genetic model significantly improved model fit. The direction of the interaction was as expected. That is, among those who reported an SLE, those with SS genotype showed an attenuated response to escitalopram. However, in those who reported no SLEs, there was no effect of 5-HTTLPR genotype on response (Table 3 , Figure 2 ). In line with previous studies 24 , 5-HTTLPR genotype was recoded to include the effects of the putative modifying SNP 
Moderating effects of other SLC6A4 variants
The only other variant that significantly moderated the effects of SLEs on antidepressant response was STin4, assuming a recessive model (Table 4 , results from all the other tested polymorphisms are shown in Supplementary Weeks from baseline
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Depression severity (MADRS)
Weeks from baseline Depression severity (MADRS) Table S1 ). There was no main effect of STin4 in the overall sample (b ¼ À0.04, 95% CI À0.04 to 0.14, Po0.1) or the escitalopram (b ¼ À0.09, 95% CI À0.03 to À0.22, Po0.1) or nortriptyline (b ¼ 0.008, 95% CI À0.13-0.13, Po0.1) arm of the study. However, the addition of an SLE by STin4 interaction to a simpler model containing the main effects of these factors significantly improved model fit in the escitalopram-treated but not in the nortriptyline-treated groups (likelihood ratio tests Po0.05 and P40.1 respectively). In this interaction, those who reported an SLE and were homozygous for the shorter alleles at this locus showed an attenuated response to escitalopram. However, STin4 genotype had no effect on response in those who reported no SLEs before treatment. 
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In the escitalopram-treated group, the occurrence of SLEs was not associated with either STin4 or 5-HTTLPR genotype, using a recessive model (5-HTTLPR,
The results of both interactions are therefore unlikely to be confounded by the effects of gene-environment correlation.
Discussion
The purpose of this study was to investigate the effects of antecedent SLEs on response to two antidepressants and examine the extent to which these effects were moderated by variation in the serotonin transporter gene.
The occurrence of antecedent SLEs predicted a more favourable response to treatment and consistent with our hypothesis, these effects were specific to those treated with escitalopram. The positive effects of antecedent SLEs on response have been reported previously; 4, 5 however, the drug-specific nature of these effects is novel. It is reasonable to suggest that as SLC6A4 moderates the effects of stress on behavioural phenotypes and encodes the main target for escitalopram, the action of this drug would be more affected by the occurrence of SLEs. However, as this is the first study to investigate drug-specific effects, this finding requires replication to test this hypothesis.
Two independent polymorphisms, 5-HTTLPR and STin4, were shown to moderate the effect of SLEs on response to escitalopram. For 5-HTTLPR, those homozygous for the S allele who also experienced one or more antecedent SLE showed a significantly poorer response to escitalopram, whereas there was no effect of genotype in those reporting no antecedent SLEs. This interaction was unaffected by the putative modifying SNP (rs25531) and in agreement with our hypothesis was drug specific, occurring only in the escitalopram-treated patients. This replicates the only previous study to test this interaction in antidepressant response in another pro-serotonergic drug (the SSRI fluvoxamine). 9 There were no main effects of STin4 on response; however, those homozygous for the shorter alleles who also experienced one or more antecedent SLE also showed significantly poorer response to escitalopram than those with one or more of the longer alleles at this locus. Again, there was no effect of genotype in the group reporting no SLEs and no effect in the nortriptyline-treated group. This finding is truly novel, as this is the first study to investigate this genetic variant. And although there is no evidence of functionality in this polymorphism yet, it may prove functional, as intronic regions are increasingly recognized as important regulators of transcription. 33 In addition, STin4 was in weak linkage disequilibrium with STin2, which has been associated with enhanced transcription of SLC6A4. 34 The inclusion of interaction terms for SLE, SLC6A4, STin4 and SLEs together explained a further 1.5% of the variance in outcome to escitalopram. This was over and above the 15% explained by baseline depression severity, randomization status, age, sex and the main effects of SLEs and genotype.
Reactive and endogenous depression It has often been suggested that variability in treatment response is a direct consequence of aetiological heterogeneity in depression. That is, aetiologically distinct subgroups exist that respond differentially to different treatments. Attempts to categorize depressive episodes as 'reactive' (occurring as a result of a stressor) or 'endogenous' (developing regardless of stress) have met with mixed success in the prediction of treatment. However, these studies suggested that the occurrence of antecedent SLEs alone indexes a 'reactive' episode. Given that the S allele of SLC6A4, life events and response to antidepressants the 5-HTTLPR is associated with a greater vulnerability to stress, a 'reactive' episode may be better characterized by a combination of both antecedent SLEs and SS genotype. It has been suggested that such a subgroup would respond better to psychotherapy than antidepressants. 35 Our results are consistent with this suggestion; specifically, the 'reactive' subgroup showed a markedly poorer response to escitalopram than their 'endogenous' counterparts.
These effects were not seen in the nortriptyline-treated patients. It is possible that the serotonin system is more sensitive to stress than the norepinepherine system and pro-serotonergic drugs are therefore more sensitive to underlying differences between endogenous and reactive depressive episodes. Although this hypothesis is consistent with our results and those reported previously, 9 further replication in comparative pharmacogenetic studies are required before any conclusions can be drawn.
Implications
Our results suggest that the effect of antecedent SLEs on response varies both by drug, and by genotype. The inconsistent findings reported thus far in studies investigating the effects of antecedent SLEs on response to antidepressants may therefore be explained by these so far unmeasured moderators. In pharmacogenetic studies of the 5-HTTLPR and response to SSRIs, as antecedent stress varies both within and between samples, the association between 5-HTTLPR and response may also vary. Future pharmacogenetic studies may therefore need to assess both genetic and environmental factors and the interplay between them in the prediction of response to antidepressants.
Limitations
Findings from this report should be interpreted in light of the following limitations. The negative findings reported in the nortriptyline-treated patients may be explained by the comparatively small sample size (n ¼ 291) and therefore reduced power in this subset compared with those treated with escitalopram (n ¼ 383). However, this is unlikely given the comparatively small effect sizes reported for both the main effects of SLEs (b ¼ 0.001) and genotype by SLE interactions (b ¼ À0.019) in this treatment group.
Although the reporting of SLEs was not associated with illness characteristics (including the severity or duration of illness or the duration of episode) or genotype, the LTE-Q was self-report and therefore subject to a number of biases, especially in the context of a current depressive illness. In addition, we were unable to include in our analyses a number of factors, including participant's level of social support, personality or quality of life, which could potentially confound the relationship between SLEs occurring before treatment and treatment response.
GENDEP is the largest prospective study to examine the interaction between SLC6A4 variants and SLEs on response to antidepressants. However, it is only powered to detect interactions of a moderate effect size. Although we detected both interactions with a nominal degree of statistical certainty these results would not survive correction for the number of polymorphisms tested. These results must therefore be interpreted with caution and require replication in an independent sample.
Finally, a recent meta-analysis has questioned the existence of an interaction between SLEs and the 5-HTTLPR in the absence of a main effect, 36 although the validity of the study has been questioned. 37, 38 Researchers remain divided on whether the genetic should be detected before testing for interactions. 39 In our analyses of the GENDEP data, we detected both a main effect of the 5-HTTLPR 16 and SLEs and their interaction on response to escitalopram.
The occurrence of antecedent SLEs predicted response to escitalopram and these effects were moderated by two variants in SLC6A4 (5-HTTLPR and STin4). This suggests that the antidepressant response phenotype may be as complex and heterogeneous as depression itself. Future pharmacogenetic or psychosocial studies should ideally consider not only environmental and genetic factors but also the interplay between these factors in the prediction of antidepressant response.
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